In our pooled analysis of the 26 cohorts, we report a strong correlation between the presence of irAEs and improved patient response and prognosis, suggesting the significance of irAEs as a predictor of anti-PD-1 therapeutic efficacy in patients with NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.